Journal
JOURNAL OF GASTROINTESTINAL ONCOLOGY
Volume 9, Issue 1, Pages 170-179Publisher
AME PUBL CO
DOI: 10.21037/jgo.2017.06.10
Keywords
Colorectal cancer (CRC); immunotherapy; checkpoint inhibition; programmed death-1 (PD-1); mismatch repair
Categories
Funding
- NCI [P30CA054174]
- NIA [P30AG044271]
Ask authors/readers for more resources
Over the past few years, the role of immunotherapy in colorectal cancer (CRC) has expanded, specifically in subsets of CRC with microsatellite instability (MSI) for which newer agents, such as programmed death-1 (PD-1) inhibitors, are efficacious. While other immunotherapeutic agents are more immature in development, they have the potential to enhance the efficacy of PD-1 inhibitors and play a role in the treatment algorithm for all subsets of CRC patients. In this review, we will discuss immunotherapeutic agents in development in patients with CRC. We will review the later phase studies that elucidate the role of immunotherapy in CRC and provide hope for changing the treatment paradigm for CRC in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available